Glucose Transporters as a Target for Anticancer Therapy
- PMID: 34439338
- PMCID: PMC8394807
- DOI: 10.3390/cancers13164184
Glucose Transporters as a Target for Anticancer Therapy
Abstract
Tumor growth causes cancer cells to become hypoxic. A hypoxic condition is a hallmark of cancer. Metabolism of cancer cells differs from metabolism of normal cells. Cancer cells prefer the process of glycolysis as a source of ATP. Process of glycolysis generates only two molecules of ATP per one molecule of glucose, whereas the complete oxidative breakdown of one molecule of glucose yields 36 molecules of ATP. Therefore, cancer cells need more molecules of glucose in comparison with normal cells. Increased uptake of glucose by these cells is due to overexpression of glucose transporters, especially GLUT1 and GLUT3, that are hypoxia responsive, as well as other glucose transport proteins. Increased expression of these carrier proteins may be used in anticancer therapy. This phenomenon is used in diagnostic techniques such as FDG-PET. It is also suggested, and there are observations, that therapeutic inhibition of glucose transporters may be a method in treatment of cancer patients. On the other hand, there are described cases, in which upregulation of glucose transporters, as, for example, NIS, which is used in radioiodine therapy, can help patients with cancer. The aim of this review is the presentation of possibilities, and how glucose transporters can be used in anticancer therapy.
Keywords: GLUT proteins; cancers therapy; sodium-dependent glucose cotransporters.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics.Chemotherapy. 2007;53(4):233-56. doi: 10.1159/000104457. Epub 2007 Jun 25. Chemotherapy. 2007. PMID: 17595539 Review.
-
A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism.Cancer Metab. 2021 Mar 26;9(1):14. doi: 10.1186/s40170-021-00248-7. Cancer Metab. 2021. PMID: 33771231 Free PMC article.
-
Glucose transporters as markers of diagnosis and prognosis in cancer diseases.Oncol Rev. 2022 Feb 22;16(1):561. doi: 10.4081/oncol.2022.561. eCollection 2022 Feb 22. Oncol Rev. 2022. PMID: 35340885 Free PMC article.
-
Metabolic Phenotype Intricacies on Altered Glucose Metabolism of Breast Cancer Cells upon Glut-1 Inhibition and Mimic Hypoxia In Vitro.Appl Biochem Biotechnol. 2023 Oct;195(10):5838-5854. doi: 10.1007/s12010-023-04373-5. Epub 2023 Jan 28. Appl Biochem Biotechnol. 2023. PMID: 36708494
-
Regulation of glucose transport by hypoxia.Am J Kidney Dis. 1999 Jul;34(1):189-202. doi: 10.1016/s0272-6386(99)70131-9. Am J Kidney Dis. 1999. PMID: 10401038 Review.
Cited by
-
Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma.Autophagy. 2023 Apr;19(4):1221-1238. doi: 10.1080/15548627.2022.2119353. Epub 2022 Sep 13. Autophagy. 2023. PMID: 36048765 Free PMC article.
-
Dual inhibitory potential of ganoderic acid A on GLUT1/3: computational and in vitro insights into targeting glucose metabolism in human lung cancer.RSC Adv. 2024 Sep 6;14(39):28569-28584. doi: 10.1039/d4ra04454a. eCollection 2024 Sep 4. RSC Adv. 2024. PMID: 39247503 Free PMC article.
-
Genetically engineering glycolysis in T cells increases their antitumor function.J Immunother Cancer. 2024 Jul 4;12(7):e008434. doi: 10.1136/jitc-2023-008434. J Immunother Cancer. 2024. PMID: 38964783 Free PMC article.
-
Modulating Glycolysis to Improve Cancer Therapy.Int J Mol Sci. 2023 Jan 30;24(3):2606. doi: 10.3390/ijms24032606. Int J Mol Sci. 2023. PMID: 36768924 Free PMC article. Review.
-
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature.Life (Basel). 2023 Aug 28;13(9):1821. doi: 10.3390/life13091821. Life (Basel). 2023. PMID: 37763225 Free PMC article. Review.
References
-
- Szablewski L., editor. Human Glucose Transporters in Health and Diseases. Cambridge Scholary Publishing, Lady Stephenson Library; Newcastle upon Tyne, UK: 2019. Expression of glucose transporters in diseases; pp. 63–227.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous